Company Reports

President Donald Trump announced on July 21 that generic drugs imported to the US will face a 100% tariff for one year starting in August 2028 and 200% thereafter. The shares of all generic drug manufacturers under our coverage are trading down on the news.

Dr. Reddy's delivered a 6% decline in revenue, missing FactSet consensus by a low-single-digit percentage, and a 56% decline in EBITDA during the first fiscal quarter. Shares were down 7% in early trading July 22 on the news.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up roughly 90% of the firm's revenue, and along with other generics manufacturers, the segment suffers low- to mid-single-digit price erosion year over year in developed markets like North America and the majority of Europe. Because headwinds exist predominantly in small-molecule oral tablets that are easy to produce and face stiff competition, the firm has shifted its pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or modes of administration. They are more difficult to manufacture which by nature limits competition. We think about 30% of Reddy's North American sales comes from complex injectables, a figure we expect to increase as the firm continues to prioritize these offerings and reinvest in its pipeline.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up roughly 90% of the firm's revenue, and along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, the firm has shifted its pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Dr. Reddy’s. A fourth of its North American sales comes from complex injectables and we expect this number to increase as the company prioritizes these offerings. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

Dr. Reddy's reported a 12% quarterly revenue decline and a diluted EPS of INR 2.6. Both figures landed below FactSet consensus. Shares are down 6%.

Dr. Reddy's reported 4.4% year-over-year revenue growth and 24.8% adjusted EBTIDA margin during the third fiscal quarter. Shares are up mildly Jan. 21 on results.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up over 85% of the firm's revenue, and along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, the firm has shifted its pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Dr. Reddy’s. A fourth of its North American sales comes from complex injectables and we expect this number to increase as the company prioritizes these offerings. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

Dr. Reddy's reported a 9.8% year-over-year revenue growth and a 26.7% EBITDA margin, down from last year but steady sequentially, for its fiscal 2026 second-quarter earnings.

Dr. Reddy's fiscal first-quarter results were highlighted by 11% revenue growth and a 2% increase in EPS. Both figures trailed FactSet estimates, which suggested 13% and 10% growth, respectively.

No-moat Dr. Reddy’s reported strong fourth-quarter earnings and ended the year on solid footing. Revenue was up 20.1% year over year and came above our expectation of 15% sales thanks to favorable utilization trends and healthy prescription demand. Growing consumer healthcare contributed nicely with the acquired nicotine replacement therapy now making up about 7% of total sales. The firm continues to invest in its biosimilars portfolio, which has seen some recent wins, including the FDA accepting partner Alvotech's denosumab (bone loss treatment) filing in March. We maintain our fair value estimate of $14 per share and see the stock trading in 3-star territory.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up over 85% of the firm's sales, and along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, the firm has shifted its pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Dr. Reddy’s. A fourth of its North American sales comes from complex injectables and we expect this number to increase as the company prioritizes these offerings. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

On April 2, President Donald Trump announced a 10% tariff on imports from all countries, effective on April 5. As for the generics industry, pharmaceuticals were among the exemptions listed in the full order, as part of Annex II. The news provided a nice boost to the Indian generic manufacturers, including Dr. Reddy’s, which saw a mild uptick in share price upon market opening. For context, India exported roughly $8.7 billion of pharmaceuticals in the US according to Reuters and close to half of all generic drugs prescribed in the US are supplied by Indian manufacturers. This comes as a relief for the Indian generics suppliers, especially since other Indian exports are subject to 26% reciprocal levies. Tariffs on the industry could have meaningfully hurt the cost advantage the Indian manufacturers have over others and put pressure on top and bottom lines.

No-moat Dr. Reddy’s reported mixed third-quarter earnings. Revenue was up 15.9% year over year thanks to strong performance across all business units, but its EBIT margin of 22.4% slipped 150 basis points. Operating expenses incurred from ramping up the consumer health business and higher research and development costs weighed down the bottom line. We maintained our fair value estimate of $14 per share after making minor adjustments to our near-term estimates, and we see shares trading near our valuation.

No-moat Dr. Reddy’s reported mixed second-quarter earnings. Total revenue was up 16.5%, higher than our expectation of low-teens growth, as solid performance across regions drove sales. But operating margins slipped from higher research and development spending as well as impairment charges related to Haloette (generic Nuvaring). After updating our model, baking in time value of money impacts, and accounting for a 5:1 stock split that was exercised on Nov. 5, we inch up our fair value estimate to $14 ($70 presplit) per share from $13.60 ($68 presplit). We see shares as fairly valued.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up over 85% of the firm's sales, and along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Dr. Reddy’s future pipeline to focus on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Dr. Reddy’s. A fourth of its North American sales comes from complex injectables and we expect this number to increase as the company prioritizes these offerings. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

No-moat Dr. Reddy’s reported stronger-than-expected first-quarter results and started off fiscal 2025 on a solid note. Robust sales growth of 13.9% year over year was fueled by North America and India generics business. After digesting results, we have ticked up our sales and profitability expectations for the full year. We are also impressed by the continued strength in solid execution of the firm. We have raised our fair value estimate to $68 per share, from $60 from our more favorable long-term expectations, and we have a higher conviction on the name currently than before, but we still see shares as overvalued.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up over 85% of the firm's sales, and along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Dr. Reddy’s future pipeline to focus on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Dr. Reddy’s. A fourth of its North American sales comes from complex injectables and we expect this number to increase as the company prioritizes these offerings. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

Wide-moat Haleon announced on June 26 that it entered into an agreement to divest its smoking cessation business outside the US to no-moat Dr. Reddy’s for GBP 500 million (GBP 458 million upfront plus performance-based payments of up to GBP 42 million). The portfolio includes brands like Nicotinell, Nicabate, and Habitrol. The deal is expected to close during the last quarter of 2024 at the earliest. We do not expect material changes to our model from this deal and maintain our fair value estimate of $8.80, or GBX 352, per share for Haleon and $60 per share for Dr. Reddy’s.

No-moat Dr. Reddy’s reported fourth-quarter earnings that came in higher than we expected. Total sales were up 12.5% year over year as demand and prescription utilization trends continue their strong momentum and help the firm end its fiscal year on a strong note. On top of solid performance, Dr. Reddy’s was busy during the quarter with a number of notable highlights, including a launch of Versavo, biosimilar of Avastin (bevacizumab), in the UK that marks the firm’s first entrance in the region’s biosimilar market. Management also spent some time during the call discussing investments in fueling its biosimilars pipeline. We think this is a sound strategy given our positive long-term outlook on the biosimilars market, particularly the US, and we think Dr. Reddy’s is well positioned to utilize its scale and low-cost manufacturing to carve out a share in the marketplace. While we now expect higher operating expenses in later years of our valuation model as we believe the firm needs to allocate higher spending in both research and development and selling, general, and administrative to ramp up its pipeline, we think this will be more than offset by higher gross margin that biosimilars and complex generics carry. After updating our fiscal 2024 numbers as well as ticking up our long-term outlook for the firm, we raise our fair value estimate to $60 from $54 per share.

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up over 85% of the firm's sales, and along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Dr. Reddy’s future pipeline to focus on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Dr. Reddy’s. A fourth of its North American sales comes from complex injectables and we expect this number to increase as the company prioritizes these offerings. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.